Amgen Inc. (AMGN)

NASDAQ: AMGN · USD

$452

+3.67 (+0.8%)· Recorded snapshot

英語版にフォールバックJA

翻訳中のため英語版を表示しています

このレポートはまだ翻訳されていません。翻訳キューが追いついたら数分後に更新してください。

StockMarketAgent Research · Analyzed 2026-09-08

Our latest published analysis: AMGN rated Buy

Amgen Inc.'s published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$492 / share

Potential value

$641 / share

Upside to FV

+12.5%

from $452

Moat

1/10

None

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$236.4B
Revenue (ttm)	38.1B
Net income (ttm)	8.7B
EPS (ttm)	$16.1
Shares out	540.6M
P/E (trailing)	28.1x
P/E (forward)	18.2x
Dividend	$10.1 (2.23%)
Volume	2,016,147
Beta	0.41

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 38.1B
Net income (ttm): 8.7B
EPS (ttm): $16.1
P/E (trailing): 28.1x
P/E (forward): 18.2x
Market cap: $236.4B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$25.98B	$26.32B	$28.19B	$33.42B	$36.75B	+9.1%
Gross profit	$19.53B	$19.92B	$19.74B	$20.57B	$26.01B	+7.4%
Operating income	$7.64B	$9.57B	$7.90B	$7.26B	$9.08B	+4.4%
Net income	$5.89B	$6.55B	$6.72B	$4.09B	$7.71B	+7.0%
EPS (diluted)	$10.28	$12.11	$12.49	$7.56	$14.23	+8.5%
EBITDA	$11.30B	$12.17B	$7.90B	$13.36B	$16.90B	+10.6%
R&D	$6.32B	$4.43B	$4.78B	$5.96B	$6.97B	+2.5%
SG&A	$5.37B	$5.41B	$6.18B	$7.10B	$7.05B	+7.1%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	5T	39.4x	10.8x	101.6%	+6.1%	+28.5%	売り
ABNB	Airbnb, Inc.	97.8B	37.5x	7.4x	16.8%	+24.4%	+28.5%	売り
ADBE	Adobe Inc.	97.1B	13.9x	3.7x	57.2%	+11.5%	-30.7%	強い買い
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	売り
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	縮小
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	縮小

Base and Bull scenarios

Base55%

Price target

$492.07

+12.5% from spot

Moderate growth and continued cash backing support the central valuation outlook. Evidence should emerge by FY2027 through annual revenue and adjusted EPS delivery.

FY2027 revenue and adjusted EPS remain near their dated mean estimates.
Revenue growth fades after the explicit forecast window.

Bull20%

Price target

$640.92

+46.6% from spot

Stronger revenue, earnings, and cash would extend growth duration without requiring a hyper-growth assumption. A low-end FY2027 earnings result would disconfirm this path.

FY2027 revenue exceeds its mean estimate.
Adjusted EPS approaches the upper end of its FY2027 range.
Cash generated from operations continues to exceed reported profit.

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($492.07). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	1.5%	2.0%	2.5%	3.0%	3.5%
5.6%	$582	$623	$679	$763	$906
6.6%	$509	$532	$561	$599	$651
7.6%	$461	$475	$492	$513	$540
8.6%	$426	$435	$447	$460	$476
9.6%	$399	$406	$414	$423	$433

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E18.2

P25 n/aP50 n/aP75 n/a

Trailing P/E27.2

P25 n/aP50 n/aP75 n/a

ROE91.5

P25 n/aP50 n/aP75 n/a

ROIC19.8

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All AMGN indicators

Market & fundamental data

Available fields

296

Groups with data

Currency

USD

Showing 296 of 296 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000318154
Company name	Amgen Inc.
Country	United States
Country code	US
CUSIP number	031162100
Earnings date	2026-11-03
Earnings time	amc
Employees	31,500
Employees change	3,500
Employees growth	12.5%
Enterprise value	$287.5B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1980
In index	SP500, NASDAQ100, DOW30
Industry	Drug Manufacturers - General
Is primary listing	Yes
Is SPAC	No
ISIN number	US0311621009
Last 10-K release date	2026-02-13
Last earnings date	2026-08-04
Last refreshed	2026-10-28
Last stock split date	1999-11-22
Last stock split type	Forward
Market cap	$244.2B
Market cap category	Mega-Cap
Next earnings date	2026-11-03
Options	Yes
Price	$451.62
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	AMGN
Tags	pharmaceuticals, weight-loss
U.S. state	California
Website	https://www.amgen.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	20.19x
Average P/E ratio (10Y)	25.24x
Average P/E ratio (3Y)	29.44x
Average P/E ratio (5Y)	25.49x
Earnings yield	3.56%
EV/Earnings	32.79x
EV/EBIT	22.53x
EV/EBITDA	16.6x
EV/FCF	28.18x
EV/Sales	7.53x
FCF / EV yield	3.55%
FCF yield	4.18%
Forward EV/Sales	7.13x
Forward P/E	19.14x
Forward P/S	6.05x
Graham number	88.48396
Graham upside	-80.34%
Industry forward P/E	18.59x
Industry P/E	36.43x
Lynch fair value	$140.95
Lynch upside	-68.69%
P/(FCF - SBC) ratio	25.13x
P/(OCF - SBC) ratio	20.31x
P/B ratio	20.72x
P/E ratio	28.06x
P/FCF ratio	23.92x
P/OCF ratio	19.5x
P/S ratio	6.39x
PEG ratio	3.86x
Price/EBITDA ratio	14.09x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	33.4%
EBITDA margin	45.33%
Effective tax rate	15.01%
FCF margin	26.71%
Gross margin	71.89%
Operating margin	33.4%
Pretax margin	27%
Profit margin	22.95%
Profit per employee	$277,556
Profitable quarters	9
Profitable years	23
Revenue per employee	$1.2M
ROA	8.67%
ROA (5Y)	8.22%
ROCE	18.14%
ROE	91.47%
ROE (5Y)	101.82%
ROIC	19.76%
ROIC (5Y)	20.52%
SBC / revenue	1.29%
Tax / revenue	4.05%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	31.6%
EPS growth (Q)	64.91%
EPS growth (QoQ)	30.84%
EPS growth 10Y	5.12%
EPS growth 3Y	2.72%
EPS growth 5Y	10.3%
EPS growth quarters	6
EPS growth years	1
FCF growth	-4.06%
FCF growth (Q)	82.58%
FCF growth (QoQ)	136.22%
FCF growth 3Y	1.66%
FCF growth 5Y	2.72%
Gross profit growth	13.09%
Gross profit growth (Q)	12.23%
Gross profit growth 3Y	11.58%
Gross profit growth 5Y	7.36%
Net income growth	32.09%
Net income growth (Q)	65.85%
Net income growth (QoQ)	30.57%
Net income growth 3Y	3.09%
Net income growth 5Y	8.76%
Net income growth quarters	6
Net income growth years	1
OCF growth	3.87%
OCF growth (Q)	75.53%
OCF growth (QoQ)	82.82%
OCF growth 10Y	2.7%
OCF growth 3Y	4.93%
OCF growth 5Y	5.48%
Operating income growth	19.55%
Operating income growth (Q)	19.33%
Operating income growth 3Y	8.67%
Operating income growth 5Y	6.56%
Revenue growth	9.1%
Revenue growth (Q)	9.53%
Revenue growth (QoQ)	16.66%
Revenue growth 10Y	5.42%
Revenue growth 3Y	12.74%
Revenue growth 5Y	8.37%
Revenue growth quarters	13
Revenue growth years	6

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-2.3B
Depreciation and amortization	$4.5B
EBIT	$12.7B
EBITDA	$17.3B
EPS	$16.09
FCF per share	$18.82
Financing cash flow	$-4.1B
Free cash flow	$10.2B
Free cash flow minus SBC	$9.7B
Gross profit	$27.4B
Income taxes	$1.5B
Investing cash flow	$-2.4B
Net borrowing	$1.3B
Net cash flow	$6B
Net income	$8.7B
Operating cash flow minus SBC	$12B
Operating income	$12.7B
Revenue	$38.1B
Stock-based compensation	$492M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	1.89
Book value per share	$21.62
Debt / EBITDA	3.27
Debt / equity	4.9
Debt / FCF	5.63
Goodwill	$18.7B
Interest coverage	4.14
Long-term assets	$60.7B
Long-term liabilities	$58.4B
Net cash (debt)	$-43.3B
Net cash / market cap	-17.8%
Net debt / EBITDA	2.51
Net debt / equity	3.71
Net debt / FCF	4.26
Piotroski F-Score	8
Property, plant and equipment	$8.5B
Shareholders' equity	$11.7B
Tangible book value	$-27.5B
Tangible book value per share	$-50.81
Total assets	$95.6B
Total cash	$14B
Total debt	$57.3B
Total liabilities	$84B
WACC	6.12%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.42
Current assets	$35B
Current liabilities	$25.5B
Current ratio	1.37
Inventory turnover	1.67
Net working capital	$915M
Quick ratio	0.95
Working capital	$9.5B
Working capital turnover	4.85

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-0.46%
Dividend growth	5.86%
Dividend growth (10Y)	10.12%
Dividend growth (3Y)	6.07%
Dividend growth (5Y)	7.64%
Dividend growth years	15
Dividend payment date	2026-09-11
Dividend payment years	16
Dividend payout frequency	Quarterly
Dividend per share	$10.08
Dividend yield	2.23%
Ex-dividend date	2026-08-21
FCF payout ratio	53.56%
Last dividend	$2.52
Payout ratio	62.63%
Shareholder yield	1.78%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	179.76%
10Y return CAGR	14.19%
10Y total return	276.96%
150-day SMA	$377.60
15Y price change	673.7%
15Y return CAGR	17.7%
15Y total return	1,052.95%
1D price change	0.82%
1M price change	8.35%
1M total return	8.35%
1W price change	2.34%
1W total return	2.34%
1Y price change	54.28%
1Y return CAGR	58.61%
1Y total return	58.56%
20-day SMA	$425.24
200-day SMA	$373.41
20Y price change	494.82%
20Y return CAGR	11.56%
20Y total return	791.23%
3M price change	19.39%
3M total return	20.09%
3Y price change	71.74%
3Y return CAGR	23.39%
3Y total return	87.89%
50-day SMA	$418.90
50-day SMA vs 200-day SMA	50over200
52-week high	$454.66
52-week high date	2026-10-28
52-week low	$288.00
52-week low date	2025-10-31
5Y price change	117.45%
5Y return CAGR	20.5%
5Y total return	154.06%
6M price change	32.05%
6M total return	33.83%
After-hours change	0.19%
After-hours close	$451.62
After-hours price	$452.46
All-time high	$454.66
All-time high date	2026-10-28
All-time low	$0.08
All-time low date	1984-11-19
Average true range (ATR)	$10.82
Average volume	2.5M
Beta (1Y)	0.21
Beta (2Y)	0.33
Beta (5Y)	0.41
Change from 52-week high	-0.67%
Change from 52-week low	56.81%
Change from all-time high	-1.2%
Change from all-time low	575,072.86%
Change from open	2.58%
Day's gap	-1.72%
Dollar volume	$910.5M
High price	$454.55
Low price	$440.26
Monthly RSI	70.02
Open price	$440.26
Position in 52-week range	79.5%
Premarket change	-0.41%
Premarket close	$447.95
Premarket price	$446.13
Premarket volume	2.1K
Previous close	$447.95
Price vs 150-day SMA	18.97%
Price vs 20-day SMA	5.64%
Price vs 200-day SMA	20.3%
Price vs 50-day SMA	7.24%
Relative volume	0.8
RSI	65.08
Sharpe ratio	1.58
Sharpe ratio (3Y)	0.71
Sharpe ratio (5Y)	0.7
Sortino ratio	2.73
Sortino ratio (3Y)	1.28
Sortino ratio (5Y)	1.31
Volume	2M
Weekly RSI	66.15
YTD price change	37.24%
YTD total return	40.05%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	539.2M
Float percentage	99.73%
Shares change (QoQ)	0%
Shares change (YoY)	0.46%
Shares held by insiders	0.17%
Shares held by institutions	83.8%
Shares outstanding	540.6M
Short % of float	2.6%
Short % of shares	2.59%
Short ratio	4.5 days

Other indicators

Additional ticker metrics that do not fit the primary research groupings.

Metric	Value
Page views	155

Deeper analysis on AMGN

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this AMGN report

What is the latest published AMGN stock rating?

Amgen Inc. is shown with Buy in the latest published report, analyzed 2026-09-08. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full AMGN analysis?

The full latest published report, analyzed 2026-09-08, lives at /stocks/AMGN/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for AMGN?

The latest published report analyzed 2026-09-08 gives AMGN a fair value of USD 492 and a potential value of USD 641. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the AMGN page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-09-08). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

BuyAMGN · Fair value $492+12.5%

Read full analysis →

Amgen Inc. (AMGN)

Our latest published analysis: AMGN rated Buy

Price

Financial snapshot

Fair-value bridge

Latest news · AMGN

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All AMGN indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Other indicators

Deeper analysis on AMGN

Frequently asked questions

レーティング履歴

Category	Score	Reading
Valuation	7.5
Management	6.5
Balance Sheet	3.5
Profitability	7.5
Revenue Growth	6.0
Risk Assessment	5.0
Competitive Moat	1.0
Earnings Quality	9.0
Capital Efficiency	7.5